Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?

BJU International

Volumn 113, Issue 2, 2014, Pages 189-199

  Tombal, Bertrand ^a   Alcaraz, Antonio ^b   James, Nicholas ^c   Valdagni, Riccardo ^d   Irani, Jacques ^e  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

high risk prostate cancer; prostate cancer; risk stratification

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; UROLOGY;

HIGH-RISK PROSTATE CANCER; PROSTATE CANCER; RISK STRATIFICATION;

COHORT STUDIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84892559227     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12469     Document Type: Article

References (86)

1. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO,. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012; 104: 1335-1342
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
3. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-1154
4. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
5. Taverna G, Benecchi L, Grizzi F, et al. Can a Gleason 6 or less microfocus of prostate cancer in one biopsy and prostate-specific antigen level <10 ng/mL be defined as the archetype of low-risk prostate disease? J Oncol 2012; 2012: 645146
6. Roach M III, Waldman F, Pollack A,. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009; 115 (13 Suppl.): 3112-3120
7. Beauval JB, Ploussard G, Soulie M, et al. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 2012; 80: 656-660
8. Collette L,. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008; 53: 6-9
9. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-1996
10. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose conformal radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial, on behalf of the RT01 investigators. Proceedings of the European Multidisciplinary Cancer Congress, Stockholm, Sweden, 24-27 September 2011. 2012
11. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962
12. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578
13. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930
14. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61: 1096-1106
15. Rosenthal SA, Sandler HM,. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 2010; 7: 31-38
16. Horwich A, Parker C, Bangma C, Kataja V,. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v129-133
17. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer. Arnhem: European Association of Urology, 2013
18. Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010; 58: 1-7
19. Briganti A, Joniau S, Gontero P, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2012; 61: 584-592
20. Hsu CY, Joniau S, Oyen R, Roskams T, van Poppel H,. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121-128
21. Huang J, Vicini FA, Williams SG, et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int J Radiat Oncol Biol Phys 2012; 83: 1141-1148
22. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
23. National Institute for Health and Clinical Excellence. Prostate Cancer: Diagnosis and Treatment. London: National Institue for Health and Clinical Excellence, 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/ cg58fullguideline.pdf. Accessed October 2013
24. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
25. Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 2009; 73: 672-678
26. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009; 103: 464-469
27. Bolla M, Hannoun-Levi JM, Ferrero JM, et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiother Oncol 2010; 97: 312-317
28. Spahn M, Weiss C, Bader P, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int 2010; 84: 164-173
29. Ploussard G, Masson-Lecomte A, Beauval JB, et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 2011; 78: 607-613
30. Alcaraz A, Burgos FJ, Cozar JM, et al. Prostate cancer in Spain: from guidelines to clinical practice. BJU Int 2011; 108: 61-66
31. Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010; 58: 687-700
32. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-4305
33. Ficarra V, Novara G, Secco S, et al. Predictors of positive surgical margins after laparoscopic robot assisted radical prostatectomy. J Urol 2009; 182: 2682-2688
34. Chalfin HJ, Dinizo M, Trock BJ, et al. Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int 2012; 110: 1684-1689
35. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-1942
36. Cooperberg MR, Broering JM, Carroll PR,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878-887
37. Yokomizo A, Murai M, Baba S, et al. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 2006; 98: 549-553
38. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61: 480-487
39. Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY,. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 940-946
40. Amin A, Partin A, Epstein JI,. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol 2011; 186: 1286-1290
41. Hayashi N, Urashima M, Kuruma H, et al. The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy. BJU Int 2008; 101: 175-180
42. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30: 293-302
43. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494
44. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-757
45. Yakar D, Debats OA, Bomers JG, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging 2012; 35: 20-31
46. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012; 61: 177-184
47. Latchamsetty KC, Borden LS Jr, Porter CR, et al. Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve? Can J Urol 2007; 14: 3429-3434
48. Heidenreich A,. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. Eur Urol 2011; 59: 495-497
49. Xylinas E, Yates DR, Renard-Penna R, et al. Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World J Urol 2013; 31: 881-886
50. Futterer JJ, Engelbrecht MR, Jager GJ, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007; 17: 1055-1065
51. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer: local staging at 3-T endorectal MR imaging-early experience. Radiology 2006; 238: 184-191
52. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195
53. Zhang JQ, Loughlin KR, Zou KH, Haker S, Tempany CM,. Role of endorectal coil magnetic resonance imaging in treatment of patients with prostate cancer and in determining radical prostatectomy surgical margin status: report of a single surgeon's practice. Urology 2007; 69: 1134-1137
54. Roethke MC, Lichy MP, Kniess M, et al. Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol 2013; 31: 1111-1116
55. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011; 107: 1411-1418
56. Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012; 110: 43-49
57. van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012; 109: 360-366
58. Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-16
59. van Gils MP, Hessels D, Hulsbergen-Van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215-1222
60. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004; 22: 307-312
61. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011; 17: 6563-6573
62. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011; 12: 245-255
63. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012; 106: 1095-1099
64. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012; 25: 471-479
65. Sreenath TL, Dobi A, Petrovics G, Srivastava S,. Oncogenic activation of ERG: a predominant mechanism in prostate cancer. J Carcinog 2012; 11: 37. Available at: http://www.carcinogenesis.com/temp/JCarcinog10137-1432959-035849. pdf. Accessed October 2013
66. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-1695
67. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-4599
68. Shah RB, Daignault S, Kunju LP, Wood JDP, Wei JT,. Significance of tertiary pattern 5 in prostate needle biopsies with Gleason score of 3+4 or 4+3 prostate cancer: pathologic correlation following radical prostatectomy. Mod Pathol 2009; 22 (Suppl. 1): 193A (Abstract #873)
69. Nanda A, Chen MH, Renshaw AA, D'Amico AV,. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009; 74: 1419-1423
70. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV,. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009; 73: 659-664
71. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC,. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 2010; 76: 710-714
72. Tendulkar RD, Reddy CA, Stephans KL, et al. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2012; 82: 1397-1404
73. Daskivich TJ, Chamie K, Kwan L, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 2011; 117: 4642-4650
74. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008; 53: 950-959
75. Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV,. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR Am J Roentgenol 2011; 197: 1369-1374
76. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242
77. Pierorazio PM, Ross AE, Lin BM, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 2012; 110: 1122-1128
78. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
79. Nguyen PL, Chen MH, Beard CJ, et al. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 2010; 116: 610-615
80. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA,. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis 2012; 15: 374-379
81. Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a u.s. Population-based cohort of men with prostate cancer. Ann Intern Med 2013; 158: 709-717
82. Vickers A, Bennette C, Steineck G, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012; 62: 204-209
83. Hamstra DA, Bae K, Pilepich MV, et al. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys 2011; 81: 1293-1301
84. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308
85. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-2111
86. Bechis SK, Carroll PR, Cooperberg MR,. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-241